GLP-1 S CERTIFICATES OF ANALYSIS 14 COAs BN-26SM30-001 Current Variant: Size: 30mg Semaglutide 29.95 mg / 31.83 mg Purity 99.842% / 99.803% BN-26SM20-001 Current Variant: Size: 20mg-10ml Semaglutide 26 mg / 25.67 mg Purity 99.625% / 99.548% BN-26SM10-001 Current Variant: Size: 10mg Semaglutide 11.38 mg / 11.37 mg Purity 99.590% / 99.661% BN-26SM05-001 Current Variant: Size: 5mg Semaglutide 5.85 mg / 6.23 mg Purity 99.299% / 99.445% BN-26SM10-003 Upcoming Variant: Size: 10mg Semaglutide 11.85 mg / 11.49 mg Purity 99.590% / 99.605% BN-26SM05-002 Upcoming Variant: Size: 5mg BN-25SM20-001 Upcoming Variant: Size: 20mg Semaglutide 21 mg Purity 99.794% BN-25SM1020-001 Previous Variant: Size: 10mg BN-25SM30-001 Previous Variant: Size: 30mg BN-25SM10-002 Previous Variant: Size: 10mg BN-25SM10-001 Previous Variant: Size: 10mg BN-25SM05-002 Previous Variant: Size: 5mg BN-25SM05-001 Previous Variant: Size: 5mg BN-25SM05-001 Previous Variant: Size: 5mg Small-Batch Research Confidence Focused research supply, documented batch by batch

As costs of GLP-1s drop below $100/month and providers like Hims/Hers emerge as scalable care platforms, a new order is forming: System C
For a large peptide like retatrutide that absorbs slowly, this limited window is a significant constraint
Additionally, BPC-157 has been shown to improve gut health, which is essential for overall well-being
Patient preferences, dosing schedules, and cost are critical factors in the selection of GLP-1 receptor agonists, with healthcare professionals playing a vital role in tailoring treatments to individual needs
Things that increase or lower the total cost of treatment